Medical and Social Expert Evaluation and RehabilitationMedical and Social Expert Evaluation and Rehabilitation1560-95372412-2092Eco-Vector3601210.18821/1560-9537-2018-21-1-94-100Research Article“DIFFICULT” ISSUES OF THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES PATIENTSBakulinI. G-SkalinskayaMariya I.MD, PhD, Associate Professor of the Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietology; Saint Petersburg, 191015, Russian Federationmskalinskaya@yahoo.comSkazyvaevaE. V-I.I. Mechnikov North-Western State Medical University15062018211-29410021072020Copyright © 2018, Eco-Vector2018The article presents “difficult” questions found by physicians in the management of inflammatory bowel diseases (IBD) patients, and also discusses and analyzes data of the Register, established by the North-West Center of the IBD (within the framework of the Federal Register of IBD patients). To date, there are many complex and unresolved issues regarding the management of IBD patients. The situation becomes especially relevant when bearing in mind these diseases start at a young and working age and pose a significant social problem. Data on the IBD prevalence rate and their separate forms vary considerably, but almost all available sources report its gain in recent years. The information displays the prevalence rate of IBD, the forms of the disease, the timing of the diagnosis, both the essence and frequency of complications. The obtained data are compared with the results of other registers. To the actual moment, despite the obvious breakthrough in the development of drugs for the treatment of IBD, not all patients can achieve an optimal response, complete relief of the inflammatory process. The discussion touches upon issues related to the immunogenicity of various genetic engineering biological products and its effect on the efficacy and safety of therapy, as well as the efficacy and safety of biosimilars in the treatment of IBD and the problems associated with predicting the effectiveness and safety of the treatment.registry: inflammatory bowel diseaseulcerative colitisCrohn’s diseasebiological therapyрегистрвоспалительные заболевания кишечникаязвенный колитболезнь Кронабиологическая терапия[Simian D., Fluxá D., Flores L., Lubascher J., Ibáñez P., Figueroa C. et al. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J. Gastroenterol. 2016; 22 (22): 5267-75.][Gearry R.B. IBD and Environment: Are There Differences between East and West. Dig. Dis. 2016; 34 (1-2): 84-9.][Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А., Шифрин О.С., Абдулганиева Д.И. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017; 1 (59): 6-30.][Осипенко М.Ф., Валуйских Е.Ю., Светлова И.О., Кулыгина Ю.А., Скалинская М.И., Бикбулатова Е.А., Краснер Я.А. Регистр воспалительных заболеваний кишечника в г. Новосибирске: итоги 2016. Сибирский научный медицинский журнал. 2017; 37( 1): 61-7.][Ye Y., Pang Z., Chen W., Ju S., Zhou C. The epidemiology and risk factors of inflammatory bowel disease. Int. J. Clin. Exp. Med. 2015; 8 (12): 22529-42.][Шелыгин Ю.А., Веселов А.В., Сербина А.А. Основные направления организации специализированной колопроктологической помощи. Колопроктология. 2017; 1 (59):76-81.][Бодрягина Е. С., Абдулганиева Д. И., Одинцова А. Х. Клинико-эпидемиологические показатели воспалительных заболеваний кишечника по Республике Татарстан. Лечащий врач. 2013; (7): 21-6.][Бакулин И.Г., Шкурко Т.В., Парфенов А.И., Князев О.В., Фадеева Н.А., Жулина Е.Ю. и др. К вопросу о распространенности и заболеваемости воспалительными заболеваниями кишечника в Москве. Фарматека. 2016; 2 (315): 69-73.][Журавлева М.В., Крысанова В.С., Веселов А.В., Лынникова Т.И. Оптимизация лекарственного обеспечения пациентов с орфанными заболеваниями с использованием зарубежного опыта и результатов фармакоэкономического анализа «Влияния на бюджет» на примере язвенного колита. Современная организация лекарственного обеспечения. 2014; (3): 19-28.][Халиф И.Л. Воспалительные заболевания кишечника: современные возможности и нерешенные проблемы в лекарственной терапии. Consilium Medicum. 2015; (1): 33-4.][Федеральное руководство по использованию лекарственных средств (формулярная система). Изд. 18-е, перераб. и дополн. Серия: Библиотека Российского национального конгресса «Человек и лекарство». М., 2017; XVIII.][Белоусова Е.А., Морозова Н.А., Никитина Н.В. Инфликсимаб (ремикейд) в лечении рефрактерных форм болезни Крона. Русский медицинский журнал. 2005; 7(1): 28-32.][Hanauer S., Feagan B., Lichtenstein G. et al. Maintenanse Infliximab for Crohn’s Disease: the ACCENT I Randomised Trial. Lancet. 2002; 359: 1541-9.][Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006; 130(2): 323-33; quiz 591.][Papp K., Bachelez H., Costanzo A., et al. Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients. Br. J. Dermatol. 2017 Jul][Lowenberg M., de Boer N.K., Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin. Exp. Gastroenterol. 2014; 7: 53-9.][Ruiz Garcia V., Jobanputra P., Burls A., Cabello J.B., Vela Casasempere P., Bort-Marti S. et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Data-base Syst Rev 2014; 9: CD007649.][Udata C., Hua S.Y., Yin D., Salts S., Meng X., Rehman M. I. et al. A phase I pharmacokinetics trial comparing PF-06438179 (a potential biosimilar) and infliximab in healthy volunteers (REFLEXTIONS B537-01). Ann. Rheum. Dis. 2014; 73(Suppl 2):494-494.][Shin D., Kim Y.H., Kim Y.S., Fuhr R., Körnicke T. A phase I pharmacokinetic study comparing SB2, an infliximab biosimilar, and infliximab reference product (Remicade®) in healthy subjects [abstract]. Ann. Rheum. Dis. 2015; 74 (Suppl 2): 459-60.][Kaur P., Chow V., Zhang N., Moxness M., Kaliyaperumal A., Markus R. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann. Rheum. Dis. 2017; 76(3): 526-33.][Amiot A., Grimaud J.C., Peyrin-Biroulet L., et al. Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clin Gastroenterol. Hepatol. 2016; 14(11): 1593-601.][Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev. 2014; 13: 24-30.][Papamichael K., Gils A., Rutgeerts P., Levesque B.G., Vermeire S., Sandborn W.J., Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm. Bowel Dis. 2015; 21: 182-97.][Colombel J.F., Sandborn W.J., Ghosh S., Wolf D.C., Panaccione R., Feagan B. ei al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am. J. Gastroenterol. 2014; 109(11): 1771-80. doi: 10.1038/ajg.2014.242][Ungar B., Chowers Y., Yavzori M., Picard O., Fudim E., Har-Noy O. et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014; 63: 1258-64. doi: 10.1136/gutjnl-2013-305259.][Baert F., Kondragunta V., Lockton S., Vande Casteele N., Hauenstein S., Singh S. et al. Antibodies to adalimumab are associated with future inflammation in Crohn’s patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2016;65:1126-31. doi: 10.1136/gutjnl-2014-307882.][Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D. et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 2010;362(15):1383-95.]